Showing 2 posts of 2 posts found.
Novartis has got its wallet out to pick up a Priority Review Voucher (PRV) from Ultragenyx, forking out $130 million …
Ultragenyx has revealed results from a Phase 3 trial into the treatment of GNE myopathy showed that its compound did …
Santen joins inaugural Global Summit for Eye Health as partner
EHP Awards 2027 open for entries following outstanding inaugural year
NHS spends £240m storing patient records as digital reforms gather pace
NHS awards national diabetes education contract to Leicester programme
InnoScot highlights NHS Scotland’s progress towards net zero healthcare